The RASopathies Network

A 501c3 organization; Our mission is to advance research of the #RASopathies by bringing stakeholders together. #rarediseases @rasnet.bsky.social 501.c.3 organization; to advance research of RASopathies by bringing together families & researchers Our mission is to advance research to improve the quality of life for RASopathies families by bringing together families, clinicians and scientists. RASopathies are a group of genetic syndromes that are as common as 1:1000. The RASopathy syndromes include: cardio-facio-cutaneous (CFC), Costello (CS), LEOPARD/NSML, Neurofibromatosis type 1 (NF1), Noonan (NS) and Legius (LS). RASopathiesNet is the product of RASopathies Network USA, a 501c3 Non-Profit, and RASopathies Network UK.
273775851
EIN
Legal name of organization: RASOPATHIES NETWORK USA
Address
rasopathiesnet.org
Web
RASopathiesnet
Twitter (1152)
rasopathiesnetwork
Facebook (1400)

News

Poslední diskuze

Nearby

Contact
RASOPATHIES NETWORK USA logo
RASOPATHIES NETWORK USA
+ Follow
4.5
Reviews
Legal name of organization: RASOPATHIES NETWORK USA
Place
About the organization

- G99 -

Statement on the impact of NIH policy changes for the RASopathies community What Are the RASopathies. 11000. Individually each of the RASopathies is rare Together they come close to 11000 Syndromes Clinics Meetings Scientific Meetings Research Publications Resources Latest News Events Headlines Approval Announcement The FDA has approved a second MEK inhibitor developed by SpringWorks Therapeutics for the treatment of plexiform neurofibroma Reading List Impact of MEK Inhibition on Childhood RASopathyAssociated Hypertrophic Cardiomyopathy Wolf C Zenker M Boleti O. et al.

Diseases, Disorders, Medical Disciplines N.E.C.
23 Vacancy More Detail